Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 21,033 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Immune System Disorders Clear all

Conditions: Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Interventions: Cobomarsen, Vorinostat; Drug
Lead sponsor: miRagen Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 16 more

Conditions: Amyloid, Amyloidosis, Spinal Stenosis, Transthyretin Amyloidosis, Primary Amyloidosis of Light Chain Type
Interventions: Biopsy; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 50 Years and older
Enrollment: 200 participants
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Lymphoma
Interventions: rituximab, yttrium Y 90 ibritumomab tiuxetan; Biological · Radiation
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 3
States / cities: Birmingham, Alabama • Stanford, California • Rochester, Minnesota

Conditions: Leukemia, Myeloid, Chronic, AML, MDS, Leukemia, Lymphocytic, Acute
Interventions: Donor Lymphocyte Infusion; Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 1 Year to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2006
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Multiple Myeloma
Interventions: Linvoseltamab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2035
U.S. locations: 13
States / cities: Los Angeles, California • Orange, California • Denver, Colorado + 9 more

Conditions: Colorectal Cancer, Gastroesophageal Cancer
Interventions: nivolumab, ipilimumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lymphangioleiomyomatosis
Interventions: Imatinib Mesylate 400Mg Capsule, Placebo - Capsule; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: New York, New York • Charleston, South Carolina

Conditions: Hiv
Interventions: CD4 CAR+CCR5 ZFN T-cells; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Allergic Conjunctivitis
Interventions: Lifitegrast, Placebo; Drug · Other
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: ixabepilone; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 3
States / cities: San Antonio, Texas

Conditions: Childhood Chronic Myelogenous Leukemia, Childhood Desmoplastic Small Round Cell Tumor, Disseminated Neuroblastoma, Metastatic Childhood Soft Tissue Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma
Interventions: tanespimycin, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Sinusitis
Interventions: XprESS device and PathAssist confirmation tools; Device
Lead sponsor: Entellus Medical, Inc.; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Phoenix, Arizona • Salem, Oregon • Charleston, South Carolina + 1 more

Conditions: Breast Carcinoma, Colorectal Adenocarcinoma, Bladder Carcinoma
Interventions: Recombinant human IL-7-hyFc (NT-I7), Vaccine sequence 1, Vaccine sequence 2; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 60 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sjogren's Syndrome, Autoimmune Diseases, Dry Eyes, Dry Mouth
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 9 Years to 21 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Multiple Myeloma
Interventions: Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 5
States / cities: Tucson, Arizona • Fort Myers, Florida • Boston, Massachusetts + 2 more

Conditions: HIV Infections, Tuberculosis
Interventions: Isoniazid, Pyridoxine hydrochloride; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 10 more

Conditions: AIDS/HIV PROBLEM
Interventions: Not listed
Lead sponsor: Gaia Medical Institute; Industry
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Myeloproliferative Disorders, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: amphotericin B deoxycholate, nystatin; Drug
Lead sponsor: Aronex Pharmaceuticals; Industry
Eligibility: 2 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2007
U.S. locations: 59
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 47 more

Conditions: Acquired Immunodeficiency Syndrome, HIV Infection
Interventions: PCLUS 3-18 MN, PCLUS 6.1 MN; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Zeposia; Drug
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 64 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Multiple Myeloma
Interventions: CC-5013; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 26
States / cities: Glendale, Arizona • Scottsdale, Arizona • Berkeley, California + 21 more

Conditions: Leukemia
Interventions: alemtuzumab; Biological
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hepatitis B, HIV Infection
Interventions: Adefovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Sclerosis (MS) - Relapsing-remitting, Upper Extremity Dysfunction
Interventions: wearable focal vibration therapy; Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Gainesville, Florida

Search by objective public record fields.

SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides

Screening for Systemic Amyloidosis Via the Ligamentum Flavum

Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

LAM Pilot Study With Imatinib Mesylate

CD4 CAR+ ZFN-modified T Cells in HIV Therapy

Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis

BMS-247550 in Treating Patients With Advanced Cancers

Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors

Sinus Balloon Dilation in Pediatric Patients

Vaccine Response With NT-I7

Examining the Immunological Process of Autoimmune Patients

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection

Rapid Oral Test for Therapeutic Response in HIV/AIDS Patients

Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer

Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection

An Examination of Cognitive Fatigue Using Functional Neuroimaging

Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia

Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients

Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study